Rapport Therapeutics (RAPP) development chief sells 20,225 shares under 10b5-1 plan

Rhea-AI Filing Summary

Rapport Therapeutics Chief Development Officer sells shares under pre-planned program. Yeleswaram Krishnaswamy completed an open-market sale of 20,225 shares of Rapport Therapeutics common stock at a weighted average price of $39.9923 per share. After the sale, he directly holds 246,426 shares. The transaction was executed under a Rule 10b5-1 trading plan adopted on December 10, 2025, indicating it was pre-scheduled rather than a discretionary trade.

Insider Trade Summary 10b5-1

Net Seller: 20,225 shares ($808,844)

Net Sell 1 txn

Insider Yeleswaram Krishnaswamy

Role Chief Development Officer

Sold 20,225 shs ($809K)

Type	Security	Shares	Price	Value
Sale	Common Stock	20,225	$39.9923	$809K

Holdings After Transaction: Common Stock — 246,426 shares (Direct, null)

Footnotes (1)

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.90 to $40.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Key Figures

Shares sold: 20,225 shares Average sale price: $39.9923 per share Post-transaction holdings: 246,426 shares +1 more

4 metrics

Shares sold 20,225 shares Open-market sale on April 17, 2026

Average sale price $39.9923 per share Weighted average for multiple trades

Post-transaction holdings 246,426 shares Direct ownership after sale

Sale price range $39.90–$40.38 per share Range of individual trade prices

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale

3 terms

Rule 10b5-1 trading plan financial

"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yeleswaram Krishnaswamy

(Last) (First) (Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/17/2026		S(1)		20,225	D	$39.9923(2)	246,426	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.90 to $40.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

	/s/ Troy Ignelzi, Attorney-in-Fact	04/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Rapport Therapeutics (RAPP) report for Yeleswaram Krishnaswamy?

Rapport Therapeutics reported that Chief Development Officer Yeleswaram Krishnaswamy executed an open-market sale of 20,225 shares of common stock. The transaction was recorded as a Form 4 filing and reflects a routine insider sale disclosed to the SEC.

At what price did the Rapport Therapeutics (RAPP) insider sell shares?

The shares were sold at a weighted average price of $39.9923 per share. A footnote explains that individual trades occurred between $39.90 and $40.38, and detailed trade breakdowns are available from the company or the SEC upon request.

How many Rapport Therapeutics (RAPP) shares does the insider hold after this sale?

Following the reported sale, Chief Development Officer Yeleswaram Krishnaswamy directly holds 246,426 shares of Rapport Therapeutics common stock. This post-transaction holding shows he retains a substantial ownership position in the company after the disclosed sale.

Was the Rapport Therapeutics (RAPP) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the transactions were carried out under a Rule 10b5-1 trading plan adopted on December 10, 2025. Such plans pre-schedule trades, indicating the timing of this sale was set in advance rather than decided spontaneously.

What does the price range in the Rapport Therapeutics (RAPP) insider sale mean?

The filing notes the shares were sold in multiple trades between $39.90 and $40.38. The reported $39.9923 figure is a weighted average price, and the insider offers to provide a full breakdown of share counts at each specific sale price upon request.